<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00407355</url>
  </required_header>
  <id_info>
    <org_study_id>05-06-09-05</org_study_id>
    <nct_id>NCT00407355</nct_id>
  </id_info>
  <brief_title>Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions</brief_title>
  <acronym>LVO</acronym>
  <official_title>A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects With Macular Edema Secondary to Vein Occlusions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter A Campochiaro, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Central and branch retinal vein occlusions are major causes of visual loss. Hemorrhage and
      capillary nonperfusion, when they involve the macula, can contribute to visual loss, but the
      major cause is macular edema. Focal and grid laser photocoagulation can sometimes provide
      benefit in patients with macular edema due to branch vein occlusions, but several laser
      treatments are often needed and recovery of vision can be very slow and incomplete 1. Laser
      photocoagulation does not provide benefit for macular edema due to central vein occlusions 2.
      Therefore, new treatments are needed.The objective of this study is to assess the bioactivity
      of 3 intravitreous injections 0.5 mg or 0.3 mg of ranibizumab in patients with macular edema
      due to central and branch retinal vein occlusions and correlate activity with peak and trough
      aqueous levels. The purpose of this research protocol is pilot study to determine if a
      randomized placebo controlled trial is warranted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase II, open-label study to investigate the bioactivity and
      pharmacodynamics of intravitreous ranibizumab in subjects with macular edema due to central
      and branch retinal vein occlusion. This pilot study will enroll 40 patients, 20 with central
      vein occlusion and 20 with branch vein occlusion. Each patient will receive three (3)
      injections of 0.5 or 0.3 mg of ranibizumab. The study consists of a 2-week screening period
      (Days -14 to -1), a 3-month treatment period, and a 9-month follow-up period. Consented
      subjects will enter the 14-day screening period to determine eligibility, including serum
      chemistry and hematology testing, urinalysis, pregnancy testing, and macular thickness based
      on optical coherence tomography measurements and fluorescein angiography. Patients who have
      reduction of visual acuity to 20/40 or worse due to foveal thickening from macular edema
      secondary to central or branch retinal vein occlusion and who meet eligibility criteria will
      be invited to enroll in the study. Baseline foveal thickness by OCT must be at least 250 um,
      which is often associated with VA of 20/40 or worse and provides sufficient thickening so
      that a treatment effect is easily detectable (Nguyen et al. 2004). Every effort will be made
      to recruit and enroll eligible patients from men and women of all ethnic and social
      backgrounds. It is expected that the 40 study subjects will be recruited over a 4-month
      period. Patients who meet entry criteria will be able to enroll in the study until the quota
      of patients has been achieved. All enrolled patients will receive either 0.5 or 0.3 mg
      injections of ranibizumab. Forty eligible subjects who have provided informed consent from
      one site (Wilmer Eye Institute at the Johns Hopkins Medical Institutions) will be enrolled,
      20 with central vein occlusion and 20 with branch vein occlusion. In each of the 2 groups, 10
      patients will be randomized to 0.5 mg of the ranibizumab, and 10 will be randomized to 0.3 mg
      of ranibizumab. Subjects will be identified and recruited through the clinic population of
      the Wilmer Eye Institute, including that of the Vitreoretinal Service and the Retinal
      Vascular Center, as well as through referral from physicians in the community. Announcement
      of the study will be made throughout the Wilmer Eye Institute, Johns Hopkins University
      School of Medicine through newsletters, pamphlets, and the clinical trials web site on the
      internet and intranet systems. Information about the study will also be sent to the community
      physicians as well as the ophthalmologists who often refer patients to the Wilmer Eye
      Institute. Every effort will be made to enroll eligible patients from men and women of all
      ethnic and social backgrounds.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity Change From Baseline at All Visits</measure>
    <time_frame>continuous through 72 mos</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal Thickness Change From Baseline at All Visits</measure>
    <time_frame>continuous through 72 mos</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Macular Edema</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>RBZ 0.3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RBZ at the 0.3 mg dose intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBZ 0.5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RBZ dose level .5 for ITV injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal injection of ranibizumab .3 dose</intervention_name>
    <description>PRN every 30 days withing retreatment criteria</description>
    <arm_group_label>RBZ 0.3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal injection of Ranibizumab .5 dose</intervention_name>
    <description>Intravitreal injection of Ranibizumab .5 dose every 30 days PRN with retreatment criteria</description>
    <arm_group_label>RBZ 0.5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent and authorization of use and disclosure of protected health
             information

          -  Age greater than or equal to 18 years

          -  Diagnosis of macular edema due to central or branch retinal vein occlusion

          -  Foveal thickness of over 250 um, as assessed by OCT

          -  Best corrected visual acuity score in the study eye of 20/40 to 20/320 inclusive
             (Snellen equivalents using the ETDRS protocol at a distance of 4 meters). Only one eye
             will be treated in the study. If both eyes are eligible, the investigator will select
             the eye to be enrolled. Visual acuity score in the non-study eye must be greater than
             25 letters (approximate Snellen equivalent 20/320).

          -  In the opinion of the investigator, decreased vision in the study eye is due to foveal
             thickening from vein occlusion and not from other obvious causes of decreased vision

          -  In the opinion of the investigator, laser photocoagulation can be withheld for at
             least 30 days after the patient has enrolled in the study

        Exclusion Criteria:

          -  Prior/Concomitant Treatment

               -  Scatter laser photocoagulation or macular photocoagulation within 3 months of
                  study entry in the study eye

               -  Use of intraocular or periocular injection of steroids in the study eye (e.g.,
                  triamcinolone) within 3 months of study entry

               -  Previous participation in a study and receipt of anti-angiogenic drugs
                  (pegaptanib sodium [EYE001], ranibizumab, anecortave acetate, protein kinase C
                  inhibitor, etc.) within 3 months of study entry Concurrent Ocular Conditions

               -  Vitreomacular traction or epiretinal membrane in the study eye evident
                  biomicroscopically or by OCT

               -  Ocular inflammation (including 1+ or above in the amount of cells) in the study
                  eye

               -  History of idiopathic or autoimmune uveitis in either eye

               -  Structural damage to the center of the macula in the study eye likely to preclude
                  improvement in visual acuity following the resolution of macular edema, including
                  atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s),
                  macular ischemia, or organized hard exudate plaque

               -  Ocular disorders in the study eye that may confound interpretation of study
                  results, including diabetic retinopathy, retinal detachment, macular hole, or
                  choroidal neovascularization of any cause (e.g., AMD, ocular histoplasmosis, or
                  pathologic myopia)

               -  Concurrent disease in the study eye that could compromise visual acuity or
                  require medical or surgical intervention during the study period

               -  Intraocular surgery in the study eye within 3 months of study entry

               -  During the study, if patients need to have cataract surgery, the patients will
                  undergo the necessary cataract or any other surgery and will continued to be
                  treated per protocol and followed.

               -  Uncontrolled glaucoma (defined as intraocular pressure greater than 30 mm Hg
                  despite treatment with anti-glaucoma medication) or previous filtration surgery
                  in the study eye

               -  Infectious blepharitis, keratitis, scleritis, or conjunctivitis (in either eye)
                  or current treatment for serious systemic infection Systemic Conditions

               -  Blood pressure exceeding 160/95 (sitting) during the screening period

               -  Renal failure requiring dialysis or renal transplant

               -  Premenopausal women not using adequate contraception

               -  Previous participation in other studies of investigational drugs (excluding
                  vitamins and minerals) within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Campochiaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2006</study_first_submitted>
  <study_first_submitted_qc>December 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2006</study_first_posted>
  <results_first_submitted>October 7, 2013</results_first_submitted>
  <results_first_submitted_qc>October 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2013</results_first_posted>
  <last_update_submitted>October 7, 2013</last_update_submitted>
  <last_update_submitted_qc>October 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Peter A Campochiaro, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>vein occlusion</keyword>
  <keyword>macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>20 patients with central retinal vein occlusion(CRVO) and 20 patients with branch retinal vein occlusion (BRVO) were enrolled at the Wilmer Eye Institute</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>CRVO</title>
          <description>10 patients- RBZ dose level .5 for ITV injection given monthly for 3 months, then prn until 6 years 10 patients- RBZ dose level .3 for ITV injection given monthly for 3 months, then .5 prn until 6 years</description>
        </group>
        <group group_id="P2">
          <title>BRVO</title>
          <description>10 patients- RBZ dose level .5 for ITV injection given monthly for 3 months, then prn until 6 years 10 patients- RBZ dose level .3 for ITV injection given monthly for 3 months, then .5 prn until 6 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CRVO</title>
          <description>10 patients- RBZ dose level .5 for ITV injection given monthly for 3 months, then prn until 6 years 10 patients- RBZ dose level .3 for ITV injection given monthly for 3 months, then .5 prn until 6 years</description>
        </group>
        <group group_id="B2">
          <title>BRVO</title>
          <description>10 patients- RBZ dose level .5 for ITV injection given monthly for 3 months, then prn until 6 years 10 patients- RBZ dose level .3 for ITV injection given monthly for 3 months, then .5 prn until 6 years</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="15.7"/>
                    <measurement group_id="B2" value="67.4" spread="11.3"/>
                    <measurement group_id="B3" value="67.1" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best Corrected Visual Acuity Change From Baseline at All Visits</title>
        <time_frame>continuous through 72 mos</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRVO</title>
            <description>10 patients- RBZ dose level .5 for ITV injection given monthly for 3 months, then prn until 6 years 10 patients- RBZ dose level .3 for ITV injection given monthly for 3 months, then .5 prn until 6 years</description>
          </group>
          <group group_id="O2">
            <title>BRVO</title>
            <description>10 patients- RBZ dose level .5 for ITV injection given monthly for 3 months, then prn until 6 years 10 patients- RBZ dose level .3 for ITV injection given monthly for 3 months, then .5 prn until 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity Change From Baseline at All Visits</title>
          <units>ETDRS letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="9.3"/>
                    <measurement group_id="O2" value="15.1" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Retinal Thickness Change From Baseline at All Visits</title>
        <time_frame>continuous through 72 mos</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRVO</title>
            <description>10 patients- RBZ dose level .5 for ITV injection given monthly for 3 months, then prn until 6 years 10 patients- RBZ dose level .3 for ITV injection given monthly for 3 months, then .5 prn until 6 years</description>
          </group>
          <group group_id="O2">
            <title>BRVO</title>
            <description>10 patients- RBZ dose level .5 for ITV injection given monthly for 3 months, then prn until 6 years 10 patients- RBZ dose level .3 for ITV injection given monthly for 3 months, then .5 prn until 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Retinal Thickness Change From Baseline at All Visits</title>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-379.9" spread="239.1"/>
                    <measurement group_id="O2" value="-216.9" spread="147.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CRVO</title>
          <description>10 patients- RBZ dose level .5 for ITV injection given monthly for 3 months, then prn until 6 years 10 patients- RBZ dose level .3 for ITV injection given monthly for 3 months, then .5 prn until 6 years</description>
        </group>
        <group group_id="E2">
          <title>BRVO</title>
          <description>10 patients- RBZ dose level .5 for ITV injection given monthly for 3 months, then prn until 6 years 10 patients- RBZ dose level .3 for ITV injection given monthly for 3 months, then .5 prn until 6 years</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Ischemic attack</sub_title>
                <description>Patient admitted to hospital, diagnosed with TIA and recovered</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mitral Valve surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Scheduled surgery for hearing problem</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitrectomy</sub_title>
                <description>Vitrectomy done due to recurrent vitreous hemorrhage in patient.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death (cause unknown)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Patient had pulmonary embolism following hip surgery and passed away.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia requiring hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Surgerical resection of breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Surgical resection of meningioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Benign pancreatic mass surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory Infection</sub_title>
                <description>This includes, common cold, sinus infections and bronchitis</description>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Campocahiro</name_or_title>
      <organization>Wilmer Eye Institute</organization>
      <phone>: 410-955-5106</phone>
      <email>pcampo@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

